Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/Safety of BICX104 Implantable Naltrexone vs Vivitrol
NCT04828694Phase 1Completed
- Sponsor
- BioCorRx
- Start
- Jun 2022
- Primary completion
- Feb 2023
- Modality
- Implantable Devices, Implantable Hydrogels, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BICX102 in opioid use disorder (OUD) (2 arms), sponsored by BioCorRx. Primary endpoints: Maximum Plasma Concentration at 140 days, Time to Maximum Plasma Concentration at 140 days and 3 more. Started Jun 2022; status: completed.
02
Drugs
BICX102
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT04828694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04828694.